Data gathered: April 15
Alternative Data for Immunovant
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 88 | Sign up | Sign up | Sign up |
| Webpage traffic | 13,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 24 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,094 | Sign up | Sign up | Sign up |
| Twitter Mentions | 30 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 66 | Sign up | Sign up | Sign up |
| Linkedin Employees | 361 | Sign up | Sign up | Sign up |
About Immunovant
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
| Price | $15.24 |
| Target Price | Sign up |
| Volume | 308,790 |
| Market Cap | $2.49B |
| Year Range | $13.31 - $34.03 |
| Dividend Yield | 0% |
| Analyst Rating | 89% buy |
| Industry | Biotechnology |
In the news
 |
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?April 8 - Yahoo Entertainment |
 |
Norges Bank Buys Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT)April 8 - ETF Daily News |
|
Raymond James Financial Inc. Purchases New Shares in Immunovant, Inc. (NASDAQ:IMVT)April 8 - ETF Daily News |
|
KLP Kapitalforvaltning AS Buys New Shares in Immunovant, Inc. (NASDAQ:IMVT)April 7 - ETF Daily News |
|
Teacher Retirement System of Texas Acquires 2,373 Shares of Immunovant, Inc. (NASDAQ:IMVT)April 1 - ETF Daily News |
|
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $41.00March 31 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 18M | -18M | -109M | -116M | -0.740 |
| Q2 '24 | 0 | 19M | -19M | -87M | -94M | -0.600 |
| Q1 '24 | 8.4M | 15M | -6.4M | -75M | -81M | -0.520 |
| Q4 '23 | 8.9M | 13M | -4.3M | -51M | -61M | -0.360 |
| Q3 '23 | 3.6M | 14M | -10M | -59M | -62M | -0.450 |
Insider Transactions View All
| Fromkin Andrew J. filed to sell 91,913 shares at $20. March 11 '25 |
| Fromkin Andrew J. filed to sell 93,297 shares at $19.5. March 11 '25 |
| Barnett Eva Renee filed to sell 321,952 shares at $20.9. February 21 '25 |
| Macias William L. filed to sell 357,353 shares at $20.9. February 21 '25 |
| Salzmann Peter filed to sell 948,786 shares at $20.9. February 21 '25 |
Similar companies
Read more about Immunovant (IMVT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Immunovant?
The Market Cap of Immunovant is $2.49B.
What is the current stock price of Immunovant?
Currently, the price of one share of Immunovant stock is $15.24.
How can I analyze the IMVT stock price chart for investment decisions?
The IMVT stock price chart above provides a comprehensive visual representation of Immunovant's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Immunovant shares. Our platform offers an up-to-date IMVT stock price chart, along with technical data analysis and alternative data insights.
Does IMVT offer dividends to its shareholders?
As of our latest update, Immunovant (IMVT) does not offer dividends to its shareholders. Investors interested in Immunovant should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Immunovant?
Some of the similar stocks of Immunovant are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.